Tarsus Pharmaceuticals Inc expected to post a loss of $1.08 a share - Earnings Preview

Tarsus Pharmaceuticals

08/08/2023 03:04

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 9 (estimated). 
    * The Irvine California-based  company is expected to report
 a
88.5% decrease in revenue to $1.76 million from $15.28 million a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Tarsus
Pharmaceuticals
Inc is for a loss of $1.08 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $50​, above​ its last closing price
of $17.01. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.92       -0.94      -0.88     Beat    6.9
 Dec. 31 2023              -0.69      -0.49     Beat    29
 Sep. 30 2022  -0.88       -0.97      -0.84     Beat    13.7​
 Jun. 30 2022  -0.61       -0.59      -0.24     Beat    59.4
 ​​Mar.        -1.06       -0.92      -0.98     Missed  -6.8
 31 2022                                                
 Dec. 31 2021  -0.76       -0.73      -0.72     Beat    1​
 Sep. 30 2021  -0.41       -0.43      -0.76     Missed  -75.1
 Jun. 30 2021  -0.40       -0.48      0.33      Beat    169.2
 This summary was machine generated August 8 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated